The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
Open accessAbstract
Purpose: To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other clinical and molecular prognosticators and to gain insight into the leukemogenic role of this microRNA. Patients and Methods: We evaluated 363 patients with primary CN-AML. miR-155 levels were measured in pretreatment marrow and blood by NanoString nCounter assays that quantified the expression of the encoding gene MIR155HG. All molecular prognosticators were assessed centrally. miR-155–associated gene and microRNA expression profiles were derived using microarrays. Results: Considering all patients, high miR-155 expression was associated with a lower complete remission (CR) rate (P < .001) and shorter disease-free survival (P = .001) and overall survival (OS; P < .001) after adjusting for age. In multivariable analyses, high miR-155 expression remained an independent predictor for a lower CR rate (P = .007) and shorter OS (P < .001). High miR-155 expressers had approximately 50% reduction in the odds of achieving CR and 60% increase in the risk of death compared with low miR-155 expressers. Although high miR-155 expression was not associated with a distinct microRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML (eg, apoptosis, nuclear factor-κB activation, and inflammation), thereby supporting a pivotal and unique role of this microRNA in myeloid leukemogenesis. Conclusion: miR-155 expression levels are associated with clinical outcome independently of other strong clinical and molecular predictors. The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA-155 is induced during the macrophage inflammatory response
O'Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G., & Baltimore, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610731104 · Cited by 1,866
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826
O'Connell, R. M., Rao, D. S., Chaudhuri, A. A., Boldin, M. P., Taganov, K. D., Nicoll, J., Paquette, R. L., & Baltimore, D. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072108 · Cited by 681
Cited by
MicroRNAome genome: A treasure for cancer diagnosis and therapy
Berindan‐Neagoe, I., Monroig, P. D. C., Pasculli, B., & Calin, G. A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21244 · Cited by 522
Acute myeloid leukemia: 2013 update on risk‐stratification and management
Estey, E. H. (2013) · American Journal of Hematology · doi:10.1002/ajh.23404 · Cited by 277
An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses
Mann, M., Mehta, A., Zhao, J. L., Lee, K., Marinov, G. K., Garcia-Flores, Y., Lu, L.-F., Rudensky, A. Y., & Baltimore, D. (2017) · Nature Communications · doi:10.1038/s41467-017-00972-z · Cited by 275
miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development
Testa, U., Pelosi, E., Castelli, G., & Labbaye, C. (2017) · Non-Coding RNA · doi:10.3390/ncrna3030022 · Cited by 267
NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia
Gerloff, D., Grundler, R., Wurm, A. A., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Madan, V, Müller-Tidow, C., Duyster, J., Tenen, D. G., et al. (2015) · Leukemia · doi:10.1038/leu.2014.231 · Cited by 135
Metadata
- Authors
- Marcucci, G., Maharry, K. S., Metzeler, K. H., Volinia, S., Wu, Y.-Z., Mrózek, K., Nicolet, D., Kohlschmidt, J., Whitman, S. P., Mendler, J. H., Schwind, S., Becker, H., Eisfeld, A.-K., Carroll, A. J., Powell, B. L., Kolitz, J. E., Garzon, R., Caligiuri, M. A., Stone, R. M., & Bloomfield, C. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-06-10
- Volume
- 31
- Issue
- 17
- Pages
- 2086-2093
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167584976
- Cited by
- 183
- References
- 4
- FWCI
- 18.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. https://app.cochat.ai/papers/10.1200/jco.2012.45.6228
- The paper
- Marcucci, G., Maharry, K. S., Metzeler, K. H., Volinia, S., Wu, Y.-Z., Mrózek, K., Nicolet, D., Kohlschmidt, J., Whitman, S. P., Mendler, J. H., Schwind, S., Becker, H., Eisfeld, A.-K., Carroll, A. J., Powell, B. L., Kolitz, J. E., Garzon, R., Caligiuri, M. A., Stone, R. M., & Bloomfield, C. D. (2013). Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.45.6228
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.